<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628704</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-015</org_study_id>
    <nct_id>NCT02628704</nct_id>
  </id_info>
  <brief_title>Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma</brief_title>
  <acronym>SCORE</acronym>
  <official_title>Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Selinexor (KPT-330), Carfilzomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With a Proteasome Inhibitor and an Immunomodulatory Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind study will compare the efficacy and assess safety of selinexor plus carfilzomib
      (Kyprolis®) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose
      dexamethasone in patients with relapsed/refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, two-arm, randomized, placebo-controlled, double-blind, multicenter study
      of relapsed/refractory multiple myeloma patients who have received at least two prior
      therapies, including a proteasome inhibitor and an IMiD.

      Patients who meet all the eligibility criteria will be randomized to one of two blinded
      treatment arms:

        -  selinexor + carfilzomib + dexamethasone

        -  placebo + carfilzomib + dexamethasone
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Assessed from the date of first dose of blinded study treatment until the date that PD assessed up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Selinexor, carfilzomib and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg of selinexor and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, selinexor will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, carfilzomib and dexamethasone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for 60 mg of selinexor) and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, Placebo (for 60 mg of selinexor) will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>The fixed dose of selinexor is 60 mg (three 20 mg tablets)</description>
    <arm_group_label>Selinexor, carfilzomib and dexamethasone</arm_group_label>
    <other_name>KCP-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for selinexor)</intervention_name>
    <description>sugar tablet manufactured to mimic selinexor tablet</description>
    <arm_group_label>Placebo, carfilzomib and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carfilzomib</intervention_name>
    <description>Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.</description>
    <arm_group_label>Selinexor, carfilzomib and dexamethasone</arm_group_label>
    <arm_group_label>Placebo, carfilzomib and dexamethasone</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.</description>
    <arm_group_label>Selinexor, carfilzomib and dexamethasone</arm_group_label>
    <arm_group_label>Placebo, carfilzomib and dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic, histologically confirmed MM, based on IMWG guidelines. Patients must have
             measurable disease as defined by at least one of the following:

               -  Serum M-protein ≥ 1.0 g/dL by serum protein electrophoresis (SPEP) or for
                  immunoglobulin (Ig) A myeloma, by quantitative IgA; or

               -  Urinary M-protein excretion at least 200 mg/24 hours; or

               -  Serum FLC ≥ 100 mg/L, provided that the serum FLC ratio is abnormal.

               -  If serum protein electrophoresis is felt to be unreliable for routine M- protein
                  measurement, then quantitative Ig levels by nephelometry or turbidometry are
                  acceptable.

          -  Must have received ≥ 2 prior anti-MM therapies including a proteasome inhibitor and an
             IMiD. The most recent proteasome inhibitor must not have been carfilzomib.

          -  Patients previously treated with carfilzomib are eligible as long as they meet the
             following criteria:

               -  Not received carfilzomib within 6 months (183 days) of Cycle 1 Day 1 (C1D1), and

               -  Carfilzomib was not part of their most recent therapy for the treatment of MM,
                  and

               -  Did not discontinue carfilzomib treatment because of adverse effects.

          -  MM that is refractory to the most recent treatment regimen. Refractory is defined as ≤
             25% response to therapy, or progression during therapy, or progression on or within 60
             days after completion of therapy.

        Exclusion Criteria:

          -  Smoldering MM.

          -  Active plasma cell leukemia.

          -  MM that does not express M-protein or serum FLC (i.e., non-secretory MM is excluded;
             plasmacytomas without M-protein or serum FLC are excluded).

          -  Documented active systemic amyloid light chain amyloidosis.

          -  Active MM involving the central nervous system.

          -  Active polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin
             changes (POEMS) syndrome.

          -  Prior autologous stem cell transplantation &lt; 1 month or allogenic stem cell
             transplantation &lt; 3 months prior to C1D1.

          -  Active graft versus host disease (after allogeneic stem cell transplantation) at C1D1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>James R. Berenson MD, Inc</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waverly Hematology</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Karyopharm</keyword>
  <keyword>selinexor</keyword>
  <keyword>KPT-330</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>SCORE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

